Automated nucleic acid extraction devices market to reach $11.05B by 2030

The automated nucleic acid extraction devices market is projected to grow 10.9% annually from $6.6 billion in 2025 to $11.05 billion by 2030, driven by molecular diagnostics, infectious disease testing, and lab automation. North America led the market in 2025 as demand rose for faster, contamination-free sample processing and higher-throughput diagnostics.

Why it matters: - Automated nucleic acid extraction devices speed up molecular testing by reducing manual labor in sample isolation, purification, and concentration. - The market's growth reflects rising demand for faster diagnostics, especially as infectious diseases and genomic testing expand. - The devices support more efficient lab workflows and higher testing throughput, which matters for healthcare systems and research labs.

What happened: - The automated nucleic acid extraction devices market is projected to rise from $6.6 billion in 2025 to $7.32 billion in 2026. - The market is expected to reach $11.05 billion by 2030. - The forecast implies a compound annual growth rate of 10.9% through the period. - North America was the largest regional market in 2025.

The details: - Automated nucleic acid extraction devices perform key steps in molecular diagnostics, including isolation, purification, and concentration of nucleic acids. - The devices reduce time and labor compared with manual extraction across the same number of samples. - Growth during the historical period was linked to surging molecular diagnostic testing, rising infectious disease incidence, wider laboratory automation, higher clinical test volumes, and improvements in nucleic acid chemistry. - Future expansion is expected to come from rapid diagnostic needs, more investment in genomic research, personalized medicine testing, broader adoption of point-of-care molecular diagnostics, and technology-driven efficiency gains. - Reported trends include more fully automated extraction systems, higher demand for high-throughput diagnostics, sample-to-result platforms, increased automation of laboratory workflows, and a stronger focus on contamination-free sample processing. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - North America's lead is tied to strong healthcare infrastructure and investment in advanced diagnostic technologies. - Data from GOV.UK in September 2023 showed tuberculosis cases in England rose 7% in the first half of 2023 from 2,251 to 2,408 compared with the same period in 2022. - The report also offers market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, key technologies and future trend analysis, plus updated graphics and tables. - Download a free sample of the report. - View the full market report.

Between the lines: - The forecast suggests automated extraction is becoming a core infrastructure layer for molecular diagnostics, not just a back-end lab tool. - The emphasis on contamination-free processing and sample-to-result platforms points to a market moving toward speed, standardization, and fewer handling errors. - Infectious disease pressure remains a major demand driver, but genomic medicine and point-of-care testing are likely to broaden the market beyond hospital labs.

What's next: - The market is expected to keep compounding at 10.9% as labs adopt more automation and high-throughput systems. - Growth should track broader use of molecular diagnostics in infectious disease testing, genomics, and personalized medicine. - North America is positioned to remain a leading market unless adoption accelerates faster in other regions.